om92 , a glp-1 enhancer mutation, is an allele of ekl-1

por Stein, Samantha A., Zucaro, Olivia F., Smith, Harold E., O'Connell, Kevin F., Spoerke, Jill M., Maine, Eleanor M., Lissemore, James L.
Publicado 2022

Molecular Biomarker Analyses Using Circulating Tumor Cells

por Punnoose, Elizabeth A., Atwal, Siminder K., Spoerke, Jill M., Savage, Heidi, Pandita, Ajay, Yeh, Ru-Fang, Pirzkall, Andrea, Fine, Bernard M., Amler, Lukas C., Chen, Daniel S., Lackner, Mark R.
Publicado 2010

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

por Schöffski, Patrick, Cresta, Sara, Mayer, Ingrid A., Wildiers, Hans, Damian, Silvia, Gendreau, Steven, Rooney, Isabelle, Morrissey, Kari M., Spoerke, Jill M., Ng, Vivian W., Singel, Stina M., Winer, Eric
Publicado 2018

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

por Spoerke, Jill M., Gendreau, Steven, Walter, Kimberly, Qiu, Jiaheng, Wilson, Timothy R., Savage, Heidi, Aimi, Junko, Derynck, Mika K., Chen, Meng, Chan, Iris T., Amler, Lukas C., Hampton, Garret M., Johnston, Stephen, Krop, Ian, Schmid, Peter, Lackner, Mark R.
Publicado 2016

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers

por Schleifman, Erica B., Desai, Rupal, Spoerke, Jill M., Xiao, Yuanyuan, Wong, Cheryl, Abbas, Ilma, O’Brien, Carol, Patel, Rajesh, Sumiyoshi, Teiko, Fu, Ling, Tam, Rachel N., Koeppen, Hartmut, Wilson, Timothy R., Raja, Rajiv, Hampton, Garret M., Lackner, Mark R.
Publicado 2014

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

por Wilson, Timothy R., Xiao, Yuanyuan, Spoerke, Jill M., Fridlyand, Jane, Koeppen, Hartmut, Fuentes, Eloisa, Huw, Ling Y., Abbas, Ilma, Gower, Arjan, Schleifman, Erica B., Desai, Rupal, Fu, Ling, Sumiyoshi, Teiko, O’Shaughnessy, Joyce A., Hampton, Garret M., Lackner, Mark R.
Publicado 2014

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast canc...

por Bardia, Aditya, Mayer, Ingrid, Winer, Eric, Linden, Hannah M., Ma, Cynthia X., Parker, Barbara A., Bellet, Meritxell, Arteaga, Carlos L., Cheeti, Sravanthi, Gates, Mary, Chang, Ching-Wei, Fredrickson, Jill, Spoerke, Jill M., Moore, Heather M., Giltnane, Jennifer, Friedman, Lori S., Chow Maneval, Edna, Chan, Iris, Jhaveri, Komal
Publicado 2022

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

por Wilson, Timothy R, Yu, Jianjun, Lu, Xuyang, Spoerke, Jill M, Xiao, Yuanyuan, O’Brien, Carol, Savage, Heidi M, Huw, Ling-Yuh, Zou, Wei, Koeppen, Hartmut, Forrest, William F, Fridlyand, Jane, Fu, Ling, Tam, Rachel, Schleifman, Erica B, Sumiyoshi, Teiko, Molinero, Luciana, Hampton, Garret M, O’Shaughnessy, Joyce A, Lackner, Mark R
Publicado 2016

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

por Clark, Travis A., Chung, Jon H., Kennedy, Mark, Hughes, Jason D., Chennagiri, Niru, Lieber, Daniel S., Fendler, Bernard, Young, Lauren, Zhao, Mandy, Coyne, Michael, Breese, Virginia, Young, Geneva, Donahue, Amy, Pavlick, Dean, Tsiros, Alyssa, Brennan, Timothy, Zhong, Shan, Mughal, Tariq, Bailey, Mark, He, Jie, Roels, Steven, Frampton, Garrett M., Spoerke, Jill M., Gendreau, Steven, Lackner, Mark, Schleifman, Erica, Peters, Eric, Ross, Jeffrey S., Ali, Siraj M., Miller, Vincent A., Gregg, Jeffrey P., Stephens, Philip J., Welsh, Allison, Otto, Geoff A., Lipson, Doron
Publicado 2018